Drug intelligence / Profile preview

GS-8670

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

GS-8670 is a small molecule farnesoid X receptor (FXR) agonist developed by Gilead Sciences, originally part of a program acquired from Medivir. FXR is a nuclear receptor that plays a central role in bile acid regulation, intestinal barrier integrity, and immune modulation. GS-8670 is being investigated for its potential to treat inflammatory bowel disease (IBD) by restoring epithelial barrier function and modulating intestinal inflammation. Preclinical studies have demonstrated its efficacy in models of colitis, and it has progressed into early-stage clinical trials.

Targets

FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on GS-8670.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-8670.

Explore the full profile